B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Intricon Corp (NASDAQ: IIN) today and set a price target of $55. The company’s shares closed on Friday at $43.25, close to its 52-week high of $46.20.
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 26.4% and a 60.9% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Cytori Therapeutics Inc, and Sorrento Therapeutics.
Currently, the analyst consensus on Intricon Corp is a Moderate Buy with an average price target of $52.50.
See today’s analyst top recommended stocks >>
Based on Intricon Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $769K. In comparison, last year the company had a net profit of $610K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets.
